Foundayo vs Wegovy Pill: Weight Loss, Side Effects, Cost, and Dosing
Foundayo and the Wegovy pill are FDA-approved once-daily oral GLP-1 medications for chronic weight management, but they use different drugs and have important practical differences. Foundayo contains orforglipron, while Wegovy tablets contain oral semaglutide 25 mg.
Wegovy tablets produced greater average weight loss in separate FDA-label trials, while Foundayo has easier dosing and a substantially lower list price. Manufacturer self-pay programs can bring the higher treatment doses of either pill to approximately $299 per month for eligible patients, although insurance coverage and program terms vary.
This article compares the U.S. tablet versions of Foundayo and Wegovy. It does not compare Foundayo with injectable Wegovy, Rybelsus, Zepbound, or unapproved research products.
Who this is for: Adults comparing oral GLP-1 weight-loss medications by results, side effects, cost, dosing convenience, and approved uses.
Who this is not for: Anyone looking for personal prescribing advice, dose-switching instructions, or a replacement for medical evaluation.
Reviewed by VerifiedSupps Editorial Team • Last reviewed: July 30, 2026
The answer-first comparison: the Wegovy pill currently has the stronger weight-loss result, while Foundayo is easier to take and has the lower list price. In their respective FDA-label trials, Wegovy 25 mg tablets produced 13.6% mean weight loss at 64 weeks, while Foundayo 17.2 mg produced 11.1% at 72 weeks in adults without type 2 diabetes.
The studies were not head-to-head, so those percentages do not prove that Wegovy will work better for every patient. Trial population, study duration, missing-data methods, adherence, side effects, and individual response all influence the final result.
Foundayo’s biggest practical advantage is flexibility. It can be taken at any time of day with or without food. Wegovy tablets must be taken in the morning on an empty stomach with no more than 4 ounces of water, followed by a wait of at least 30 minutes before food, drinks, or other oral medications.
For a deeper look at Lilly’s medication, see orforglipron for weight loss. Readers comparing oral diabetes medications may also want to review orforglipron vs Rybelsus.
Key Takeaways
- Foundayo contains orforglipron, a small-molecule GLP-1 receptor agonist developed by Eli Lilly.
- Wegovy tablets contain oral semaglutide 25 mg and are made by Novo Nordisk.
- Wegovy tablets produced 13.6% mean weight loss at 64 weeks in their FDA-label trial.
- Foundayo 17.2 mg produced 11.1% mean weight loss at 72 weeks in adults without type 2 diabetes.
- Foundayo can be taken with or without food; Wegovy tablets require strict empty-stomach morning dosing.
- Foundayo’s list price is $649 per 30-day supply, compared with $1,349.02 per Wegovy package.
- Current self-pay programs price the higher treatment doses of both medications at about $299 per month for eligible patients.
- Both medications commonly cause gastrointestinal side effects and carry important GLP-1 safety warnings.
Which is better: Foundayo or the Wegovy pill?
Wegovy tablets appear better for maximizing average weight loss, while Foundayo appears better for simple dosing and lower list-price exposure. Neither medication is automatically the better choice for every patient.
Both medications activate GLP-1 receptors, which can reduce appetite, increase fullness, slow gastric emptying, and improve glucose regulation. Their molecular structures and oral-delivery strategies are different.
Mechanism
- Foundayo: Contains orforglipron, a nonpeptide small molecule that activates the GLP-1 receptor.
- Wegovy pill: Contains semaglutide, a peptide GLP-1 receptor agonist formulated for absorption through the stomach.
- Weight-loss pathway: Both primarily support weight loss by reducing appetite and calorie intake rather than directly burning body fat.
- What they do not target: Neither activates GIP or glucagon receptors like some dual- and triple-agonist drugs in development.
| Category | Foundayo | Wegovy pill |
|---|---|---|
| Active drug | Orforglipron | Semaglutide |
| Drug structure | Small molecule, nonpeptide | Peptide |
| Frequency | Once daily | Once daily |
| Food restrictions | None required | Strict empty-stomach dosing |
| Average label-based weight loss | 11.1% at the highest dose | 13.6% |
| List price | $649 per 30-day supply | $1,349.02 per package |
| Cardiovascular risk-reduction indication | Not included in the current label | Yes, for eligible adults with established cardiovascular disease |
People interested in medications with additional receptor targets can compare CT-388 for weight loss, VK2735, and ribupatide. Those are separate investigational drugs and should not be treated as approved alternatives.
How much weight can you lose with Foundayo vs Wegovy tablets?
Wegovy tablets produced approximately 2.5 percentage points more average weight loss than Foundayo’s highest approved dose in separate FDA-label trials. The difference was larger among participants reaching at least 15% or 20% weight loss.
The Foundayo trial lasted 72 weeks and enrolled adults with obesity, or overweight with at least one weight-related condition, without type 2 diabetes. The Wegovy pill trial lasted 64 weeks and studied a broadly similar population without type 2 diabetes.
| Trial result | Foundayo 17.2 mg | Wegovy tablet 25 mg |
|---|---|---|
| Study duration | 72 weeks | 64 weeks |
| Mean weight loss | 11.1% | 13.6% |
| Placebo weight loss | 2.1% | 2.4% |
| Lost at least 5% | 71.5% | 76.3% |
| Lost at least 10% | 54.5% | 59.8% |
| Lost at least 15% | 35.9% | 47% |
| Lost at least 20% | 18.4% | 27.9% |
Lilly also reported that people who remained on Foundayo treatment lost an average of 12.4% at the highest dose. Novo Nordisk reported a 16.6% treatment-adherent result for oral semaglutide 25 mg. These efficacy-estimand figures may better represent continuous treatment, but they are less conservative than the FDA label’s intention-to-treat estimates.
The most defensible conclusion is that Wegovy tablets produced greater average weight loss in available studies, but only a randomized head-to-head obesity trial could make a direct efficacy comparison.
For comparison with injectable and investigational semaglutide alternatives, see retatrutide vs semaglutide and the latest retatrutide approval status.
Are Foundayo or Wegovy pill side effects worse?
Both medications commonly cause gastrointestinal side effects, but the available labels do not provide a perfect apples-to-apples comparison. Foundayo’s label gives dose-specific common-event percentages, while the Wegovy label says tablet reactions were generally similar to the established Wegovy safety profile.
At Foundayo’s highest dose, nausea occurred in 35% of patients, diarrhea in 25%, constipation in 24%, and vomiting in 24%. Most gastrointestinal reactions were mild or moderate and occurred more often during dose escalation.
| Safety measure | Foundayo 17.2 mg | Wegovy tablet 25 mg |
|---|---|---|
| Nausea | 35% | Not separately itemized in the tablet label table |
| Diarrhea | 25% | Common; exact tablet percentage not separately itemized |
| Constipation | 24% | Common; exact tablet percentage not separately itemized |
| Vomiting | 24% | Common; exact tablet percentage not separately itemized |
| Stopped because of any adverse reaction | Approximately 8% across pooled Foundayo groups | 6.9% |
| Stopped because of GI reactions | 6% at 17.2 mg | 3.4% |
Both medications carry boxed warnings concerning thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Other important warnings overlap and include:
- Acute pancreatitis
- Severe gastrointestinal reactions
- Kidney injury related to vomiting, diarrhea, and dehydration
- Gallbladder disease, including gallstones and cholecystitis
- Hypoglycemia when combined with insulin or insulin-secretagogue medications
- Serious hypersensitivity reactions
- Potential pulmonary aspiration during anesthesia or deep sedation
- Diabetic retinopathy monitoring in people with type 2 diabetes
Major appetite suppression can also make it harder to consume enough protein and calories to preserve lean tissue. Our guide to muscle loss during incretin-based weight reduction explains why resistance training and adequate protein remain important. See also how much protein you actually need.
How much do Foundayo and the Wegovy pill cost?
Foundayo has the lower manufacturer list price, but current self-pay programs make the higher treatment doses of both medications similarly priced for eligible patients. The actual pharmacy cost depends heavily on dose, insurance coverage, savings eligibility, and where the prescription is filled.
As of July 30, 2026, Foundayo’s list price is $649 per 30-day supply. The Wegovy pill’s list price is $1,349.02 per package. List price is not necessarily the amount a patient pays after insurance or manufacturer savings.
| Cost category | Foundayo | Wegovy pill |
|---|---|---|
| Manufacturer list price | $649 per 30-day supply | $1,349.02 per package |
| Commercial insurance savings | As low as $25 per month for eligible patients | As low as $25 per month, subject to maximum savings and eligibility |
| Starting-dose self-pay | $149 for 0.8 mg | $149 for 1.5 mg |
| Second escalation dose | $199 for 2.5 mg | $149 for 4 mg through August 31, 2026; then $199 |
| Higher treatment doses | $299 for 5.5 mg and 9 mg | $299 for 9 mg and 25 mg |
| Highest Foundayo doses | $299 for 14.5 mg or 17.2 mg when refill conditions are met; regular self-pay price $349 | Not applicable; 25 mg is the maintenance dose and is currently $299 through the listed self-pay program |
| Eligible Medicare participants | May qualify for $50 per month through the Medicare GLP-1 Bridge | May qualify for $50 per month through the Medicare GLP-1 Bridge |
Foundayo’s lower list price could matter when insurance applies coinsurance as a percentage of the medication’s price. However, manufacturer-direct self-pay pricing makes the maintenance-level cash costs much closer than the list prices suggest.
Current manufacturer programs have important restrictions:
- Savings offers may be limited to approved uses and eligible U.S. patients.
- Commercial savings cards generally exclude government-insured patients.
- Self-pay purchases may not count toward an insurance deductible or out-of-pocket maximum.
- Foundayo’s $299 price for 14.5 mg and 17.2 mg requires qualifying refills within 45 days.
- The $149 Wegovy 4 mg offer was scheduled to end August 31, 2026, after which the listed price becomes $199.
- Manufacturers can modify or discontinue savings programs, so prices should be rechecked before publishing updates or filling a prescription.
How does Foundayo dosing compare with Wegovy pill dosing?
Both are once-daily tablets that require gradual dose escalation, but Foundayo has a much simpler administration routine. Wegovy tablets require consistent fasting conditions to support semaglutide absorption.
The FDA-approved escalation schedules are:
| Treatment period | Foundayo | Wegovy tablets |
|---|---|---|
| Days 1–30 | 0.8 mg once daily | 1.5 mg once daily |
| Days 31–60 | 2.5 mg once daily | 4 mg once daily |
| Days 61–90 | 5.5 mg once daily | 9 mg once daily |
| Day 91 onward | May remain at 5.5 mg or increase at intervals of at least 30 days through 9 mg, 14.5 mg, and a maximum of 17.2 mg based on response and tolerability | 25 mg once daily maintenance dose |
| Food timing | With or without food | Empty stomach in the morning |
| Water requirement | No special water-volume restriction | Water only, up to 4 ounces |
| Waiting period | None specified | Wait at least 30 minutes before food, drinks, or other oral medications |
Foundayo may be easier for people who take several morning medications, drink coffee immediately after waking, work changing shifts, or struggle with strict fasting routines.
Wegovy’s administration rules are not optional. Taking oral semaglutide with food, too much water, or another medication can alter absorption. Patients who cannot tolerate the 25 mg tablet maintenance dose may be considered for a switch to Wegovy injection under the prescribing label.
Foundayo also has more medication-interaction considerations involving CYP3A4 inhibitors and inducers. The label may limit the maximum Foundayo dose or advise avoiding certain combinations, making a complete medication review important.
Who should choose Foundayo, and who may prefer the Wegovy pill?
Foundayo may be the better practical fit for someone prioritizing simple administration and lower list price. Wegovy tablets may be the better fit for someone prioritizing greater average oral GLP-1 weight loss or an established cardiovascular risk-reduction indication.
| Priority or situation | Potentially better fit | Reason |
|---|---|---|
| Highest average oral GLP-1 weight loss | Wegovy pill | Its FDA-label trial produced greater average weight loss. |
| Easiest daily administration | Foundayo | It can be taken with or without food and without a fasting window. |
| Lower list price | Foundayo | Its $649 list price is substantially below Wegovy’s $1,349.02 package price. |
| Self-pay at a higher treatment dose | Approximately tied | Current eligible manufacturer programs price both around $299 per month. |
| Established cardiovascular disease | Potential Wegovy advantage | Wegovy tablets include a cardiovascular risk-reduction indication for eligible adults. |
| Multiple morning medications | Potential Foundayo advantage | Wegovy’s fasting and separation rules may complicate the morning routine. |
| Preference for semaglutide specifically | Wegovy pill | It contains the established semaglutide molecule. |
Neither medication should be combined with another GLP-1 receptor agonist. Switching between them should be managed by a prescriber because the doses are not equivalent and both require titration.
Patients who need greater average weight loss than either oral pill typically provides may discuss approved injectable options with a clinician. Research candidates such as CT-388 vs tirzepatide, MariTide, and retatrutide remain separate from currently approved treatment decisions.
References
- U.S. Food and Drug Administration. Foundayo Prescribing Information. Revised April 2026.
This FDA label supports Foundayo’s indication, administration instructions, dose escalation, weight-loss results, adverse-reaction frequencies, contraindications, warnings, and drug-interaction information.
- U.S. Food and Drug Administration. Wegovy Prescribing Information. Revised May 2026.
This FDA label supports Wegovy tablet dosing, empty-stomach administration, the 25 mg maintenance dose, weight-loss results, switching guidance, adverse-reaction information, warnings, and cardiovascular indication.
- Eli Lilly and Company. Foundayo Pricing Information.
This source supports the $649 list price for a 30-day Foundayo supply and explains why actual out-of-pocket costs depend on insurance and savings eligibility.
- Eli Lilly and Company. Foundayo Coverage and Savings.
This source supports current Foundayo self-pay prices by dose, commercial savings-card details, refill conditions for higher doses, and program limitations.
- Novo Nordisk. Wegovy Cost, Coverage, and Savings Resources.
This source supports the Wegovy pill’s $1,349.02 list price, dose-specific self-pay pricing, commercial savings information, and current offer limitations.
- Novo Nordisk. Medicare GLP-1 Bridge Information for Wegovy.
This source supports the potential $50 monthly cost for eligible Medicare Part D participants and the temporary program’s eligibility and timing restrictions.
- U.S. Food and Drug Administration. FDA Approves Foundayo. April 1, 2026.
This FDA announcement supports Foundayo’s approval date and current U.S. regulatory status.
- Novo Nordisk. Wegovy Pill Approved in the U.S. December 22, 2025.
This source supports the approval and launch context for oral semaglutide 25 mg, as well as the treatment-adherent OASIS 4 weight-loss result.
- Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, for Obesity. New England Journal of Medicine. 2025.
This peer-reviewed ATTAIN-1 publication supports the efficacy and safety evidence behind Foundayo’s obesity indication.
- Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults With Overweight or Obesity. New England Journal of Medicine. 2025.
This peer-reviewed OASIS 4 publication supports the weight-loss and tolerability evidence behind Wegovy 25 mg tablets.
FAQ
Is Foundayo the same as the Wegovy pill?
No. Foundayo contains orforglipron, a nonpeptide small-molecule GLP-1 receptor agonist. Wegovy tablets contain oral semaglutide.
Which pill causes more weight loss?
Wegovy tablets produced greater average weight loss in separate FDA-label trials: 13.6% at 64 weeks compared with 11.1% at 72 weeks for Foundayo’s highest approved dose. The medications have not been directly compared in a completed obesity trial.
Which costs less, Foundayo or Wegovy tablets?
Foundayo has the lower list price at $649 per 30-day supply, compared with $1,349.02 for a Wegovy package. Current self-pay programs price the higher treatment doses of both medications at approximately $299 per month for eligible patients.
Which is easier to take?
Foundayo is easier to take because it can be taken with or without food. Wegovy tablets must be taken on an empty stomach in the morning with no more than 4 ounces of water, followed by a wait of at least 30 minutes.
Are Foundayo side effects different from Wegovy pill side effects?
They overlap substantially because both activate GLP-1 receptors. Nausea, vomiting, diarrhea, constipation, abdominal discomfort, reflux symptoms, dehydration, gallbladder events, and reduced appetite are important concerns with both.
Can you take Foundayo and Wegovy together?
No. Using Foundayo with another GLP-1 receptor agonist is not recommended, and Wegovy should not be combined with another semaglutide product or GLP-1 medication.
Can you switch from Foundayo to Wegovy tablets?
A switch may be possible, but it should be planned by a prescriber. The doses are not equivalent, and a transition may require a new titration schedule, glucose monitoring, and review of side effects and other medications.
Does the Wegovy pill protect against heart attacks and strokes?
Wegovy tablets are approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Foundayo’s current FDA label does not include that indication.
Medical Disclaimer
This article is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Foundayo and Wegovy tablets are prescription GLP-1 receptor agonists that should be used only under the care of a licensed healthcare professional. They may cause serious side effects and are not appropriate for everyone, including people with certain thyroid cancer risk factors, MEN 2, pregnancy considerations, pancreatitis history, severe gastrointestinal disease, gallbladder concerns, kidney risks from dehydration, diabetic retinopathy, medication interactions, or planned procedures involving anesthesia or deep sedation. Prices and savings programs can change. Do not start, stop, combine, or switch GLP-1 medications without medical guidance.
